Understanding the Market | GENFLEET-B turns from decline to rise of over 9%, first patient enrolled in the study of GFH375 combination therapy for advanced solid tumors completed
I'm PortAI, I can summarize articles.
GENFLEET-B's stock price turned from decline to increase in the afternoon, with an increase of over 9%. As of the time of publication, the stock price rose by 6.71%, reported at HKD 28.3, with a trading volume of HKD 44.5183 million. The company announced that its KRAS G12D inhibitor GFH375 combination therapy has completed the enrollment of the first patient at Peking University Cancer Hospital, with the study approved by the National Medical Products Administration, involving combination with cetuximab or chemotherapy. The efficacy and safety of GFH375 will be reported at the 2025 ESMO Annual Meeting
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments